A Study of LY2409021 in Healthy Participants
| Status: | Completed |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 18 - 85 |
| Updated: | 10/31/2018 |
| Start Date: | August 2014 |
| End Date: | September 2014 |
A Single Dose Pharmacokinetic Study of LY2409021 Tablet Administered in Healthy Subjects
The study involves a single dose of LY2409021 taken by mouth. The purpose of this study is to
determine how much LY2409021 enters the bloodstream and how long the body takes to get rid of
the drug after the dose. This study will last approximately 28 days, not including screening.
Screening can occur within 30 days prior to the start of the study.
determine how much LY2409021 enters the bloodstream and how long the body takes to get rid of
the drug after the dose. This study will last approximately 28 days, not including screening.
Screening can occur within 30 days prior to the start of the study.
Inclusion Criteria:
- Healthy males or females as determined by medical history
- Satisfactory clinical laboratory and physical examination tests
- Have a body mass index (BMI) of 18 to 32.0 kilograms per meter squared (kg/m^2)
Exclusion Criteria:
- Abnormal electrocardiograms (ECGs)
We found this trial at
1
site
Click here to add this to my saved trials
